The economic evaluation of pharmacotherapies for Parkinson's disease

被引：12

作者：

Coyle, D

Barbeau, A

Guttman, M

Baladi, JF

机构：

[1] Univ Ottawa, Ottawa Hlth Res Inst, Ottawa Hosp, Clin Epidemiol Unit,Dept Med & Epidemiol, Ottawa, ON K1Y 4E9, Canada

[2] Univ Ottawa, Ottawa Hlth Res Inst, Ottawa Hosp, Clin Epidemiol Unit,Dept Community Med, Ottawa, ON K1Y 4E9, Canada

[3] Novartis Pharma Canada Inc, Dorval, PQ, Canada

[4] Ctr Movement Disorders, Markham, ON, Canada

[5] Univ Toronto, Div Neurol, Dept Med & Psychiat, Toronto, ON, Canada

来源：

PARKINSONISM & RELATED DISORDERS | 2003年 / 9卷 / 05期

关键词：

health economics; cost-effectiveness; economic evaluation; Parkinson's disease;

D O I：

10.1016/S1353-8020(02)00116-5

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

As well as the significant clinical effects of Parkinson's disease (PD), the disease places a high economic burden on society. Given the scarcity of health care resources, it is becoming increasingly necessary to demonstrate that new therapies for PD provide value for money in comparison with other potential interventions. This paper outlines the basic techniques of cost-effectiveness analysis and its application to PD. These techniques are illustrated by a recent economic evaluation of entacapone for use in Canada. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：301 / 307

页数：7

共 36 条

[1]

AMINOFF MJ, 1998, HARRISONS PRINCIPLES, V14, P2356

[2]

UNCERTAINTY IN THE ECONOMIC-EVALUATION OF HEALTH-CARE TECHNOLOGIES - THE ROLE OF SENSITIVITY ANALYSIS [J].

BRIGGS, A ;

SCULPHER, M ;

BUXTON, M .

HEALTH ECONOMICS, 1994, 3 (02) :95-104

[3]

An introduction to Markov modelling for economic evaluation [J].

Briggs, A ;

Sculpher, M .

PHARMACOECONOMICS, 1998, 13 (04) :397-409

[4]

The role of entacapone in the management of Parkinson's disease [J].

Brooks, DJ ;

Forsyth, D ;

Playfer, JR ;

Williams, AC .

HOSPITAL MEDICINE, 2000, 61 (04) :267-271

[5]

Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.3.CO

[6]

2-N

[7]

*CAN COORD OFF HLT, 1997, GUID EC EV PHARM

[8]

Trials and tribulations - Emerging issues in designing economic evaluations alongside clinical trials [J].

Coyle, D ;

Davies, L ;

Drummond, MF .

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1998, 14 (01) :135-144

[9]

The economic impact of Parkinson's disease - An estimation based on a 3-month prospective analysis [J].

Dodel, RC ;

Singer, M ;

Kohne-Volland, R ;

Szucs, T ;

Rathay, B ;

Scholz, E ;

Oertel, WH .

PHARMACOECONOMICS, 1998, 14 (03) :299-312

[10]

Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205

← 1 2 3 4 →